FDA approves world's first PTSD wearable as ASCO 2026 opens
First FDA-approved PTSD wearable enters clinic; IVF, prostate cancer, and oncology trial-access AI tools debut at ASCO 2026.
By Dr. Asher Knippel
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting opened today in Chicago — and this week has delivered an unusual cluster of clinical and regulatory milestones: a historic first approval in PTSD neuromodulation, AI tools clearing regulatory review in reproductive medicine and oncology, and new trial-design frameworks aimed at cutting drug development timelines by a fifth or more.
Friday, 29 May: World's first neuromodulation device for PTSD wins FDA De Novo approval
Neurovalens, a Belfast-based health technology company, has received De Novo authorisation from the U.S. Food and Drug Administration for Modius Spero — the first time the FDA has authorised a neuromodulation device specifically for the symptoms of post-traumatic stress disorder (PTSD).
Modius Spero is a wearable worn behind the ear that delivers low-level electrical stimulation to the vestibular nerve, a sensory pathway connected to the brain regions that regulate arousal and the stress response. The mechanism is that repeated gentle stimulation of this pathway can recalibrate the hypervigilance circuits that sustain core PTSD symptoms, without the cognitive side-effects common to pharmacological approaches.
The De Novo clearance followed a clinical programme enrolling more than 300 participants. PTSD affects an estimated 13 million Americans each year; veterans are disproportionately impacted. Neurovalens plans to make Modius Spero available on prescription to U.S. military veterans through the Department of Veterans Affairs starting July 2026. The device is intended for adults aged 22 and older and requires no surgical implantation. Prior attempts at neurostimulation for PTSD — including transcranial magnetic stimulation — produced mixed results or faced significant access barriers; a wearable, home-usable device changes the practical equation considerably.
(Sources: Health Tech World, Silicon Republic, MedPage Today)
Friday, 29 May: FDA closes comment period on AI-enabled clinical trials pilot
The FDA's public comment window on a proposed pilot programme — "AI-Enabled Optimisation of Early-Phase Clinical Trials" — closed today. Announced on 28 April, the initiative would allow pharmaceutical companies to run cloud-connected trials in which patient safety data and dose-escalation decisions are updated in near real time using machine learning, rather than at fixed review intervals.
The FDA estimates this approach could reduce total trial timelines by 20–40%. AstraZeneca and Amgen are already running initial trials under the framework. The submissions received will inform formal guidance — including what safeguards are required, what success metrics apply, and which trial phases are eligible.
The move reflects a broader FDA strategy: in May the agency launched Elsa 4.0, an upgraded internal AI tool for all staff, and consolidated more than 40 data sources into a new platform called HALO (Harmonised AI and Lifecycle Operations for Data), designed to accelerate internal regulatory review.
(Sources: FDA.gov, Government Executive, Bank Info Security, JD Supra, Mintz)
Thursday, 28 May: AI embryo-assessment tool clears FDA for IVF clinics
The FDA has cleared Embryo Predict, an AI-powered tool from Alife Health, to assist fertility specialists in selecting embryos for transfer during in vitro fertilisation (IVF). The clearance is supported by a prospective, randomised, multi-centre clinical trial enrolling 440 patients across seven U.S. clinics — one of the more rigorous study designs for a fertility AI clearance to date.
The tool analyses images of embryos taken during culture and assigns an AI score based on patterns learned from thousands of embryos and their outcomes. Published research found that fertility specialists independently disagree on the top embryo choice 34.6% of the time, underscoring the clinical need. The device requires no new lab hardware and integrates with existing microscopes and imaging systems.
Embryo Predict already holds CE Mark under EU Medical Device Regulation, making it commercially available across the US, Europe, and the UK. For patients in Cyprus and elsewhere in the EU, this means the tool is entering or already present in regional fertility clinics. IVF live-birth rates across the EU average around 30% per transfer; AI-assisted selection aims to narrow that gap incrementally, though this clearance study was not designed to demonstrate a live-birth endpoint directly.
(Sources: MedTech Dive, PR Newswire, FemTech Insider, Morningstar)
Friday, 29 May: ASCO 2026 opens with oncology AI trial-access data
At the ASCO 2026 Annual Meeting (29 May–2 June, Chicago), Massive Bio unveiled Reticulum Nexus™, a multi-agent AI system designed to bridge the chronic gap between cancer trial availability and patient enrolment. A peer-reviewed study across 3,804 patients found the platform matched patients to eligible trials four times faster than conventional review methods.
The platform coordinates patient engagement, electronic medical record ingestion, eligibility pre-screening, and trial activation in a single workflow. Fewer than 5% of adult cancer patients in the US enrol in a clinical trial — a persistent bottleneck limiting both the evidence base and access to experimental therapies. AI pre-screening targets the most labour-intensive step — manual eligibility review — without replacing clinical judgment on final enrolment decisions.
Also at ASCO, Tempus AI presented multi-centre prospective data from six U.S. community health systems showing its AI clinical decision support platform increased biomarker testing rates for early-stage non-small cell lung cancer by 13–24 percentage points within 90 days of diagnosis. Since guideline-directed treatment for lung cancer requires EGFR, ALK, and PD-L1 testing, these testing-rate gains have direct implications for which patients receive targeted therapy.
(Sources: Business Wire, Las Vegas Sun News)
Friday, 29 May: Myriad Genetics adds AI Gleason-upgrade risk score to prostate cancer test
Myriad Genetics launched the Prolaris® + AI Test today, combining three data streams for prostate cancer risk stratification: a molecular genomic score (the established Prolaris® assay), clinical-pathological features including PSA level and Gleason grade, and a new AI digital pathology metric — the Artificial Intelligence–Gleason Upgrade Risk score (AI-GUR).
AI-GUR is derived from whole-slide image analysis of biopsy tissue and predicts the probability that a tumour's Gleason grade will be upgraded at the next surveillance biopsy — the central question for men managing prostate cancer under active surveillance who are deciding whether to proceed to radical treatment. A validation study found AI-GUR a statistically significant predictor of Gleason upgrade at first follow-up biopsy. The test launches across US laboratories starting today (initially excluding New York State).
Prostate cancer is the most common cancer in men across the EU, including Cyprus, where screening uptake and access to molecular testing remain uneven. Composite risk tools integrating genomics and digital pathology aim to reduce both over-treatment of indolent cancers and under-treatment of aggressive ones — the persistent clinical tension in prostate cancer management.
(Sources: BioSpace, GlobeNewswire)
The articles in this roundup are journalistic reporting and do not constitute medical advice. Before making any change to your treatment, medication, or care plan, please consult a qualified clinician.